awmsg logo



sufentanil (Dzuveo®)


Reference No. 3885

Publication date:
06/11/2018


Appraisal information

sufentanil (Dzuveo®) 30 microgram sublingual tablet


Company: FGK Representative Service GmbH
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 02/11/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, sufentanil (Dzuveo®) cannot be endorsed for use within NHS Wales for the management of acute moderate to severe pain in adult patients
Statement of Advice (SOA)
Download